Want to see CLNN full AI Analyst Report?
CLNN Stock Chart & Stats
$5.39
-$0.09(-1.64%)
At close: 4:00 PM EDT
$5.39
-$0.09(-1.64%)
Day’s Range― - ―
52-Week Range$3.30 - $13.50
Previous Close$5.39
Volume48.26K
Average Volume (3M)71.50K
Market Cap
$64.40M
Enterprise Value$73.51
Total Cash (Recent Filing)$5.94M
Total Debt (Recent Filing)$22.05M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Aug 17, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.25
Shares Outstanding12,778,307
10 Day Avg. Volume66,888
30 Day Avg. Volume71,500
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-3.29
Price to Sales (P/S)289.36
P/FCF Ratio-3.11
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$32.20Price Target Upside497.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.79
Revenue Forecast (FY)$207.40K
Bulls Say, Bears Say
Bulls Say
Regulatory Progress Toward Accelerated ApprovalFDA feedback that CNM-Au8 data may support accelerated approval (with neurofilament light as a potential surrogate) creates a viable regulatory pathway. That structural endorsement focuses development priorities, shortens time-to-market if accepted, and underpins a clear plan (NDA planned Q3 2026, Phase 3 confirmatory study 2027) for commercialization-dependent value creation.
Near-term Liquidity Relief Via Debt AmendmentsNote amendments that push principal and interest to a later maturity materially reduce near-term cash outflows and lower default pressure. By deferring monthly payments until maturity and extending dates into 2027, management has lengthened runway to reach regulatory milestones, improving the company’s ability to execute without immediate refinancing.
Equity Financing To Fund Critical DevelopmentA $7M registered direct offering provides dedicated capital for NDA preparation, manufacturing scale-up, and Phase 3 planning. This targeted financing directly supports milestone-driven development activities, meaningfully extending cash runway and reducing near-term dilution risk tied to urgent operating cash needs while progressing toward commercialization.
Bears Say
Persistent High Cash BurnSustained negative operating and free cash flow (~-$18.1M TTM) indicates operations consume significant cash each year. With free cash flow tracking net losses and worsening versus the prior period, the company remains dependent on external financing to fund R&D and trials, increasing execution risk if capital markets tighten or planned financings falter.
Weak Balance Sheet And Leverage RiskNegative equity alongside roughly $22M of debt and modest total assets (~$21.7M TTM) reduces financial flexibility and raises refinancing and covenant risk. This structural leverage profile constrains optionality: additional capital raises or debt restructuring may be necessary, potentially diluting shareholders or altering governance if milestones slip.
Minimal Revenue And Large Operating LossesWith virtually no product revenue ($0.13M TTM, down 33%) and a substantial net loss (~-$33.5M), Clene operates as a pre-commercial biotech whose economics hinge on trial success and approval. The persistent gap between costs and revenue means reaching sustainable profitability requires successful regulatory outcomes and effective commercialization execution—outcomes that are uncertain.
Clene News
CLNN FAQ
What was Clene Inc’s price range in the past 12 months?
Clene Inc lowest stock price was $3.30 and its highest was $13.50 in the past 12 months.
What is Clene Inc’s market cap?
Clene Inc’s market cap is $64.40M.
When is Clene Inc’s upcoming earnings report date?
Clene Inc’s upcoming earnings report date is Aug 17, 2026 which is in 16 days.
How were Clene Inc’s earnings last quarter?
Clene Inc released its earnings results on May 14, 2026. The company reported -$0.69 earnings per share for the quarter, missing the consensus estimate of -$0.637 by -$0.053.
Is Clene Inc overvalued?
According to Wall Street analysts Clene Inc’s price is currently Undervalued.
Does Clene Inc pay dividends?
Clene Inc does not currently pay dividends.
What is Clene Inc’s EPS estimate?
Clene Inc’s EPS estimate is -0.37.
How many shares outstanding does Clene Inc have?
Clene Inc has 12,778,307 shares outstanding.
What happened to Clene Inc’s price movement after its last earnings report?
Clene Inc reported an EPS of -$0.69 in its last earnings report, missing expectations of -$0.637. Following the earnings report the stock price went up 8.462%.
Which hedge fund is a major shareholder of Clene Inc?
Currently, no hedge funds are holding shares in CLNN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Clene Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.20 (497.40% Upside)
$32.20 (497.40% Upside)
Blogger Sentiment
Bullish
CLNN Sentiment 100%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Increased
By 50.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
47.26%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-14.41%
Trailing 12-Months
Company Description
Clene Inc
Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submission in individuals battling amyotrophic lateral sclerosis (ALS). The company has successfully concluded a Phase 2 proof-of-concept trial for those with early manifestations of ALS. Furthermore, two open-label, investigator-blinded Phase 2 trials assessing brain energy metabolism have been finished. An ongoing Phase 2 trial is investigating CNM-Au8's potential to mitigate visual pathway deficits stemming from chronic optic neuropathy, aiming for remyelination in stable relapsing Multiple Sclerosis patients. A Phase 2 clinical investigation targeting Parkinson's Disease patients is also slated for commencement. Beyond its leading candidate, Clene's pipeline extends to include CNM-AgZn17. This gel formulation, comprising silver and zinc ions, is in development to combat infectious diseases and hasten wound recovery. Additionally, CNM-ZnAg acts as a broad-spectrum antiviral and antibacterial compound, designed to address various infectious conditions like COVID-19, while also offering immune support for symptom alleviation. For oncology, CNM-PtAu7 is a gold-platinum CSN therapeutic agent currently in development. The company also distributes dietary supplements, featuring rMetx, a liquid supplement containing zinc-silver ions, and KHC46, an aqueous gold supplement with trace amounts of gold nanoparticles. Clene Inc. maintains its headquarters in Salt Lake City, Utah.
CLNN Stock 12 Month Forecast
Average Price Target
$32.20
▲(497.40% Upside)
Technical Analysis
Dyadic International
―
Akari Therapeutics
―
Estrella Immunopharma
―
AN2 Therapeutics, Inc.
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
37.89% Insiders
2.96% Mutual Funds
0.79% Other Institutional Investors
55.57% Public Companies and
Individual Investors